-
BioPharma Dive – AI / Data3 weeks agoAspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection
Aspen Neuroscience presented positive Phase 1/2 data for its stem cell-derived therapy. Elsewhere, Aldeyra lost over half its market value following a rejection from the FDA.
-
BioPharma Dive – AI / Data3 weeks agoCrossbow raises $77M for new cancer immunotherapies
Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead program CBX-250.
Uncategorized34 minutes ago
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
Uncategorized40 minutes ago
STAT+: Gilead to buy cancer biotech Tubulis for more than $3 billion
Uncategorized53 minutes ago
